News Norgine gets first EU approval for WHIM syndrome therapy Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
Patients Prevention for a healthier, more productive society During Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine.
News Norgine on a growth charge again with Theravia takeover deal Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of France's Theravia for an undisclosed sum.
Views & Analysis Why Norgine is embracing AI chatbots for medical information When European pharma company Norgine saw an unmet need in how patients were seeking information on one of its brands, they decided to implement a chatbot to help people find the answers they nee
News Norgine rejoins ABPI after eight year absence ABPI says Norgine's support will be important during Brexit.
News NICE backs UCB drug as first uncontrolled gMG therapy UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
